Paper · 26947331

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Cristofanilli M and 17 others. Lancet Oncol, 2016. Cited by 1,458 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Papers, record 26947331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26947331

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.; PubMed
Journal: Lancet Oncol; PubMed
Year: 2016; PubMed
Publication types: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/26947331/; PubMed
DOI: https://doi.org/10.1016/s1470-2045(15)00613-0; PubMed
The journal: https://conductscience.org/library/journal-index/100957246; PubMed
Citations, by iCite: 1,458; iCite
Relative citation ratio, by iCite: 45.9; iCite
Revised in PubMed: 2026-01-27; PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Cristofanilli M	Massimo
2	Turner NC	Nicholas C
3	Bondarenko I	Igor
4	Ro J	Jungsil
5	Im SA	Seock-Ah
6	Masuda N	Norikazu
7	Colleoni M	Marco
8	DeMichele A	Angela
9	Loi S	Sherene
10	Verma S	Sunil

1 to 10 of 18Source PubMed

See all 18 authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Breast Neoplasms	Major topic
Estradiol	Major topic
Phosphatidylinositol 3-Kinases	Major topic
Piperazines	Major topic
Pyridines	Major topic
Erb-b2 Receptor Tyrosine Kinases	Major topic
Adult
Aged
Class I Phosphatidylinositol 3-Kinases
Disease-Free Survival
Double-Blind Method
Female
Fulvestrant
Humans
Middle Aged
Mutation
Neoplasm Metastasis
Neoplasm Recurrence, Local
Treatment Outcome

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
			P30CA060553	NIH

Source NIH RePORTER

Trials8

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record	Source
NCT01942135	Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)	Derived from the trial	Yes	ClinicalTrials.gov
NCT02947685	Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer	Background		ClinicalTrials.gov
NCT03644186	To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)	Background		ClinicalTrials.gov
NCT03697577	CDK and Body Composition Study	Background		ClinicalTrials.gov
NCT04920708	Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression	Background		ClinicalTrials.gov
NCT05004142	Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin	Background		ClinicalTrials.gov
NCT05163106	Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole	Background		ClinicalTrials.gov
NCT06489821	STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer	Background		ClinicalTrials.gov

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers	Source
Erratum in	27,300,673	Correction to Lancet Oncol 2016; 17: 429.	https://conductscience.org/library/papers/27300673	PubMed
Erratum in	27,733,295	Correction to Lancet Oncol 2016; 17: 431, 434, 435.	https://conductscience.org/library/papers/27733295	PubMed
Comment in	26,947,329	Palbociclib: efficacious but predictive biomarkers still needed.	https://conductscience.org/library/papers/26947329	PubMed

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by974

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,458 citations.

PMID	Title	Journal	Year	In Papers	Source
42,930,149	Lactate Dehydrogenase-to-Albumin Ratio and Glasgow Prognostic Score as Prognostic Markers in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.	Curr Oncol	2026	https://conductscience.org/library/papers/42930149	PubMed
42,923,905	CDK4/6 Inhibitors in the Treatment of Advanced ER/PR-Positive, HER2-Negative Breast Cancer: An Updated Single-Center Analysis of Real-World Data.	Breast Care (Basel)	2026	https://conductscience.org/library/papers/42923905	PubMed
42,897,132	Entinostat plus exemestane for hormone receptor-positive advanced breast cancer: long-term overall survival results from the EOC103A3101 randomized controlled trial.	Signal Transduct Target Ther	2026	https://conductscience.org/library/papers/42897132	PubMed
42,891,744	Surgical resection versus stereotactic body radiotherapy for oligometastatic breast cancer to the liver.	Clin Exp Metastasis	2026	https://conductscience.org/library/papers/42891744	PubMed
42,883,756	Identification of a Conserved Temporal Molecular Response Signature to CDK4/6 Inhibition Through Multi-Omics Integration Across Cancer Cell Lines.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42883756	PubMed
42,872,060	Prognostic value of hormone receptor expression in patients with HR+/HER2- advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study.	EClinicalMedicine	2026	https://conductscience.org/library/papers/42872060	PubMed
42,804,029	Circulating tumour DNA and its clinical relevance in predicting progression-free survival and overall survival in patients with advanced breast cancer: a systematic review and meta-analysis.	Breast Cancer Res Treat	2026	https://conductscience.org/library/papers/42804029	PubMed
42,794,737	Genetic Variation in NR1I2 and Palbociclib Safety and Prognosis in Advanced Breast Cancer: An Exploratory Multicenter Study.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42794737	PubMed
42,792,625	Upfront Versus Deferred CDK4/6 Inhibitor Use in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study.	Biomedicines	2026	https://conductscience.org/library/papers/42792625	PubMed
42,761,341	Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties.	Explor Target Antitumor Ther	2026	https://conductscience.org/library/papers/42761341	PubMed

1 to 10 of 974

See all 974 cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
CDK4	1,019	PubTator's text mining	https://conductscience.org/library/genes/1019	NCBI Gene
CDK6	1,021	PubTator's text mining	https://conductscience.org/library/genes/1021	NCBI Gene
ERBB2	2,064	PubTator's text mining	https://conductscience.org/library/genes/2064	NCBI Gene
NR4A1	3,164	PubTator's text mining	https://conductscience.org/library/genes/3164	NCBI Gene
PIK3CA	5,290	PubTator's text mining	https://conductscience.org/library/genes/5290	NCBI Gene

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
FULVESTRANT	CHEMBL1358	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL1358	ChEMBL
PALBOCICLIB	CHEMBL189963	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL189963	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26947331

GET https://conductscience.org/api/papers/v1/26947331/cited_by?page=2

API reference For AI assistants